Pinned
That you are here - that life exists and identity,
That the powerful play goes on, and you may contribute a verse.
Walt Whitman, Leaves of Grass (1892)
Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
6,474 posts
Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
@APassaroMD
Med oncologist interested in lung cancer, biomarkers and drug development
- 🔥📡 kaboooom! Amazing news at @AACR #Targets21 🎯KRAS G12D is therapeutic TARGET! @Mirati presented the structure of MRTX1133, the reversible KRAS #G12D inhibitor. Great news for #LCSM, #Pancreatic Cancer #CRC, and more 🙌🙌🙌
- The light is On💡 Out our @NEJM editorial on Trastuzumab Deruxtecan in HER2-Mutant NSCLC by Bob Li et al. nejm.org/doi/full/10.10… #LCSM #LungCancer @peters_solange
- 💡🔥Out today, the Oncogene-addicted metastatic NSCLC ESMO Guideline. A significant effort to improve the management of patients w/ #lungcancer harbouring 🔟 different gene alterations! This is an amazing manuscript & I am glad to be a part of it #LCSM sciencedirect.com/science/articl…
- 🆕🌟I’m very proud to share our last manuscript titled “ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell #LungCancer” #LCSM A global effort to improve the management of EGFR-positive disease Thanks to all the authors!!! annalsofoncology.org/article/S0923-…
- Happy to share our latest #review on overcoming therapy resistance in EGFR-mutant, just published with @NatureCancer 💡rdcu.be/ciK5E
- 💥#ASCO22 #LCSM Concomitant publication @NEJM for the KRAYSTAL-1 ph2 trial, just presented by @AlexSpiraMDPhD Another step forward for the KRAS-g12C mutant NSCLC…& much more is coming! nejm.org/doi/full/10.10…
- #ASCO21 we are ready to go!💨 Here, some of the most interesting abstract on #LungCancer #LCSM that will be presented, very soon! Take a look at that & enjoy 👁🗨
- 💥🔥just out in @Annals_Oncology, the NEW @myESMO guideline for non-oncogene addicted metastatic NSCLC #LCSM ‼️ Honoured to be part of this important document (waiting for oncogene addicted one), lead by @HendriksLizza & @MartinReck2
- #ESMO19 #LCSM Do you want to know how to treat patients with NSCLC and predictive biomarkers? Here, an excellent vademecum exploring available and upcoming target agents for #lungcancer by @dplanchard
- 🧿Neoadjuvant Chemotherapy Plus Immuno in Early-Stage Resectable NSCLC #LCSM Happy to share our NADIM OGR companion article,just published in @JCO_ASCO focusing on endpoints,study design & challenges in the field of perioperative #immuno 📌Find it here ascopubs.org/doi/abs/10.120…
- 👁🗨#ESMO20 the day after🔈 #LungCancer take-home 📬 ▪️KN024:31.9% 5yr-OS w/ 1L IO ▪️CROWN:PFS-HR Lorlatinib 0.28.🆕standard?Maybe no! ▪️LungART:PORT for pN2 cannot be reccomended as SoC ▪️ADAURA: towards approval ▪️Sotirasib for KRAS G12C ORR 32.3%/DoR 10.9m ▪️BLU-945:👈🏻😉 #LCSM
- 🚀 Excited to announce our latest @CellCellPress publication on "Cancer biomarkers: Emerging trends and clinical implications for personalized treatment." An important collaboration shedding light on promising avenues in cancer research.📑✨ sciencedirect.com/science/articl…
